Creating a New Diversified Biopharmaceutical Company

The Combination of AbbVie and Allergan

Investor Presentation
June 25, 2019
NO OFFER OR SOLICITATION

This presentation is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the acquisition or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. In particular, this presentation is not an offer of securities for sale into the United States. No offer of securities shall be made in the United States absent registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from, or in a transaction not subject to, such registration requirements. Any securities issued in the acquisition are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act of 1933, as amended. The acquisition will be made solely by means of the Scheme Document (or, if applicable, the Takeover Offer document), which will contain the full terms and conditions of the acquisition, including details with respect to the AbbVie shareholder vote in respect of the acquisition. Any decision in respect of, or other response to, the acquisition, should be made only on the basis of the information contained in the Scheme Document.

IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC

In connection with the proposed Acquisition, Allergan will file with the Securities Exchange Commission (the “SEC”) a Proxy Statement, which will include the Scheme Document. BEFORE MAKING ANY VOTING DECISION, ALLERGAN’S SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT, INCLUDING THE SCHEME DOCUMENT, AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED ACQUISITION OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT (IF ANY) CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED ACQUISITION AND THE PARTIES TO THE PROPOSED ACQUISITION. Allergan’s shareholders and investors will be able to obtain, without charge, a copy of the Proxy Statement, including the Scheme Document, and other relevant documents filed with the SEC (when available) from the SEC’s website at http://www.sec.gov. Allergan shareholders and investors will also be able to obtain, without charge, a copy of the Proxy Statement, including the Scheme Document, and other relevant documents (when available) by directing a request by mail or telephone to Allergan, or from Allergan’s website.

PARTICIPANTS IN THE SOLICITATION

Allergan and certain of its directors and executive officers and employees may be considered participants in the solicitation of proxies from the shareholders of Allergan in respect of the transactions contemplated by the Scheme Document. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the shareholders of Allergan in connection with the proposed transactions, including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the Scheme Document when it is filed with the SEC. Information regarding Allergan’s directors and executive officers is contained in Allergan’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and its Proxy Statement on Schedule 14A, dated March 22, 2019, which are filed with the SEC, and certain of Allergan’s Current Reports on Form 8-K, which were filed with the SEC on February 19, 2019, March 22, 2019 and May 1, 2019.

FORWARD LOOKING STATEMENTS

This presentation contains certain forward-looking statements with respect to a possible acquisition involving AbbVie and Allergan and AbbVie’s, Allergan’s and/or the combined group’s estimated or anticipated future business, performance and results of operations and financial condition, including estimates, forecasts, targets and plans for AbbVie and, following the acquisition, if completed, the combined group. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the possibility that a possible acquisition will not be pursued, failure to obtain necessary regulatory approvals or required financing or to satisfy any of the other conditions to the possible acquisition, adverse effects on the market price of AbbVie’s shares of common stock or Allergan’s ordinary shares and on AbbVie’s or Allergan’s operating results because of a failure to complete the possible acquisition, failure to realize the expected benefits of the possible acquisition, failure to promptly and effectively integrate Allergan’s businesses, negative effects relating to the announcement of the possible acquisition or any further announcements relating to the possible acquisition or the consummation of the possible acquisition on the market price of AbbVie’s shares of common stock or Allergan’s ordinary shares, significant transaction costs and/or unknown or inestimable liabilities, potential litigation associated with the possible acquisition, general economic and business conditions that affect the combined companies following the consummation of the possible acquisition, changes in global, political, economic, business, competitive, market and regulatory forces, future exchange and interest rates, changes in tax laws, regulations, rates and policies, future business acquisitions or disposals and competitive developments. These forward-looking statements are based on numerous assumptions and assessments made in light of AbbVie’s or, as the case may be, Allergan’s experience and perception of historical trends, current conditions, business strategies, operating environment, future developments and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The factors described in the context of such forward-looking statements in this presentation could cause AbbVie’s plans with respect to AbbVie, Allergan’s or AbbVie’s actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and persons reading this presentation are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this presentation. Additional information about economic, competitive, governmental, technological and other factors that may affect AbbVie is set forth in Item 1A, “Risk Factors,” in AbbVie’s 2018 Annual Report on Form 10-K, which has been filed with the SEC, the contents of which are not incorporated by reference into, nor do they form part of, this presentation. Additional information about economic, competitive, governmental, technological and other factors that may affect Allergan is set forth in Item 1A, “Risk Factors,” in Allergan’s 2018 Annual Report on Form 10-K, which has been filed with the SEC, the contents of which are not incorporated by reference into, nor do they form part of, this presentation.

Any forward-looking statements in this presentation are based upon information available to AbbVie and/or its board of directors as of the date of this presentation and, while believed to be true when made, may ultimately prove to be incorrect. Subject to any obligations under applicable law, neither AbbVie nor any member of its board of directors undertakes any obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, to conform any forward-looking statement to actual results, future events, or to changes in expectations. All subsequent written and oral forward-looking statements attributable to AbbVie or its board of directors or any person acting on behalf of any of them are expressly qualified in their entirety by this paragraph.
STATEMENT REQUIRED BY THE IRISH TAKEOVER RULES
The directors of AbbVie accept responsibility for the information contained in this presentation. To the best of the knowledge and belief of the directors of AbbVie (who have taken all reasonable care to ensure that such is the case), the information contained in this presentation for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

DEALING DISCLOSURE REQUIREMENTS
Under the provisions of Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013 (the “Irish Takeover Rules”), if any person is, or becomes, ‘interested’ (directly or indirectly) in, 1% or more of any class of ‘relevant securities’ of AbbVie or Allergan, all ‘dealings’ in any ‘relevant securities’ of AbbVie or Allergan (including by means of an option in respect of, or a derivative referenced to, any such ‘relevant securities’) must be publicly disclosed by not later than 3:30 pm (Irish time) on the ‘business’ day following the date of the relevant transaction. This requirement will continue until the date on which the Scheme becomes effective or on which the ‘offer period’ otherwise ends. If two or more persons co-operate on the basis of any agreement, either express or tacit, either oral or written, to acquire an ‘interest’ in ‘relevant securities’ of AbbVie or Allergan, they will be deemed to be a single person for the purpose of Rule 8.3 of the Irish Takeover Rules.

Under the provisions of Rule 8.1 of the Irish Takeover Rules, all ‘dealings’ in ‘relevant securities’ of Allergan by AbbVie or ‘relevant securities’ of AbbVie by Allergan, or by any party acting in concert with either of them, must also be disclosed by no later than 12 noon (Irish time) on the ‘business’ day following the date of the relevant transaction.

A disclosure table, giving details of the companies in whose ‘relevant securities’ ‘dealings’ should be disclosed, can be found on the Irish Takeover Panel’s website at www.irishtakeoverpanel.ie.

NO PROFIT FORECAST / ASSET VALUATIONS
No statement in this presentation is intended to constitute a profit forecast for any period, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for AbbVie or Allergan as appropriate. No statement in this presentation constitutes an asset valuation.

GENERAL
Appendix I to the Rule 2.5 announcement issued jointly by AbbVie and Allergan on June 25, 2019 (the “Rule 2.5 Announcement”) contains further details of the sources of information and bases of calculations set out in this presentation.

This presentation contains certain statements as to estimated synergies arising from the Acquisition. There are various material assumptions underlying the synergies estimate which may result in the synergies being materially greater or less than estimated. The estimates should therefore be read in conjunction with the bases and assumptions for these synergy numbers which are set out in Appendix I of the Rule 2.5 Announcement. The synergies have been reported on in accordance with Rule 19.3(b) of the Irish Takeover Rules by (i) PricewaterhouseCoopers and (ii) Morgan Stanley. Copies of their respective reports are included in Appendix IV and Appendix V to the Rule 2.5 Announcement. The synergy and earnings enhancement statements in this presentation should not be construed as a profit forecast or interpreted to mean that the earnings of AbbVie and/or Allergan in 2019, or in any subsequent period, would necessarily match or be greater than or be less than those of AbbVie and/or Allergan for the relevant financial period or any other period.

All references in this presentation: (a) to an entity being the “largest” or similar, are by reference to 2018 publicly reported revenues of that entity and of its peer companies; (b) to 2019 revenue of the combined company are based on revenue guidance for 2019 provided on recent earnings calls; (c) to 2020 revenues are derived from an average of the following broker estimates: (i) in relation to AbbVie and Humira revenues: Societe Generale, Atlantic Equities, SVB Leerink, Piper Jaffray, Wolfe Research, Morgan Stanley, BMO, Cowen and Credit Suisse; and (ii) in relation to Allergan: JP Morgan, Credit Suisse, Guggenheim, RBC, Suntrust, Piper Jaffray, Wells Fargo, Citi, Leerink, Cantor, Cowen, Morgan Stanley; (d) to AbbVie’s anticipated growth relative to peers, are by reference to estimated revenue compound annual growth rate (CAGR) from 2018-2023 sourced from analysts’ consensus estimates as of June 21, 2019, with GSK revenue estimates sourced from Bloomberg, and all other peer company revenue estimates sourced from Nasdaq IR. Combined revenue growth for AbbVie (ex-Humira) and Allergan is based on AbbVie’s internally estimated revenue CAGR for 2018-2023 period. AbbVie considers its peer companies for this purpose to be AZN, GSK, BMY, MRK, JNJ, ROG, SAN, PFE, LLY, GILD, NVS and AMGN.

The release, publication or distribution of this presentation in or into certain jurisdictions may be restricted by the laws of those jurisdictions. Accordingly, copies of this presentation and all other documents relating to the Acquisition are not being, and must not be, released, published, mailed or otherwise forwarded, distributed or sent in, into or from any such restricted jurisdictions. Persons receiving such documents (including, without limitation, nominees, trustees and custodians) should observe these restrictions. Failure to do so may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, the companies involved in the proposed Acquisition disclaim any responsibility or liability for the violations of any such restrictions by any person.

Any response in relation to the Acquisition should be made only on the basis of the information contained in the Scheme Documents or any document by which the Acquisition and the Scheme are made. Allergan shareholders are advised to read carefully the formal documentation in relation to the proposed Acquisition once the Scheme Documents have been dispatched.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.
Creates a New Diversified Biopharmaceutical Company, Well-Positioned for Sustainable Growth

1. Unique opportunity to acquire attractive and durable growth assets at a highly compelling value

- Leverage AbbVie commercial strength and international infrastructure across Allergan’s therapeutic segments
- Significantly expands AbbVie’s presence in attractive high growth markets
- Brings leadership positions with Medical Aesthetics and Neuroscience; further builds out gastroenterology and women’s health franchises

2. Provides immediate scale and profitability to AbbVie’s Growth Platform (ex-Humira), with sales of more than $30BN\(^*\) in 2020 and best-in-industry growth expected well into the next decade

- Following transaction, AbbVie comprised of two high value components:
  - **New AbbVie Growth Platform**
    - Attractive business, with growing leadership positions across high value therapeutic areas with diversified payors; expected to drive high-single-digit annual revenue growth over the next decade
    - Growth Platform will have the R&D capacity for continued significant investment in promising, innovative science
  - **Humira**
    - Remains an important component of leading Immunology franchise as new assets launch and expand indications
    - Generating robust cashflow through U.S. loss of exclusivity in 2023 and beyond; earmarked to rapidly pay down incremental debt

3. Deal mitigates impact of 2023 U.S. Humira LOE

- Addresses product concentration concerns and secures attractive growth prospects through the next decade under any U.S. Humira erosion scenario
- Humira will continue to generate robust cash flow that exceeds requirements for paydown of incremental debt by 2023

4. Potential for substantial shareholder value creation

- Immediately accretive to earnings; expected to contribute 10% accretion to adjusted EPS over the first full year of combination, with peak accretion of greater than 20%**
- Expect >$2BN of pre-tax synergies and other cost reductions in year 3***, while leaving investments in key growth franchises untouched
- Generates significant operating cash flow to reduce debt, support a growing dividend and pursue additional mid-to-late stage pipeline assets

---

\(^*\)Not intended as revenue guidance; See disclosure statement on Slide 3. **The statement that this transaction is earnings accretive should not be interpreted to mean that the earnings per share in the current or any future financial period will necessarily match or be greater than those for the relevant preceding financial period.***Represents annual synergies reached after 3 years post-close. Synergy statement has been prepared in accordance with Irish Takeover Rules.
## Financially Compelling Transaction

### Deal Terms

- Each Allergan share will be exchanged for $120.30 in cash and 0.8660 share of combined company (fixed exchange ratio). AbbVie shareholders to own 83% of AbbVie (on a fully diluted basis) and Allergan shareholders to own 17%.

- Total consideration of $188.24 per Allergan share based on AbbVie’s closing stock price on 6/24/2019. Premium of 45% to Allergan’s closing price on 6/24/2019; compares favorably relative to recent transactions of similar scale.

- Transaction ROIC to exceed corporate cost of capital in first full year of combination, offering 10% earnings accretion in first full year, with peak accretion of greater than 20%.*

- Closing anticipated by early 2020, subject to regulatory and shareholder approvals and other customary closing conditions.

- Upon completion of the transaction, the company will continue to be incorporated in Delaware and have principal executive offices in North Chicago, Illinois.

- Richard Gonzalez will continue to serve as chairman and CEO through Humira LOE event in 2023; AbbVie Board of Directors will include two Allergan board members, including Brent Saunders.

<table>
<thead>
<tr>
<th>Creates Significant Shareholder Value</th>
<th>Generates &gt;$2BN in Synergies and Cost Savings in Year 3*</th>
<th>Significant EPS Accretion: 10% Accretion Over the First Full Year of Combination Peaking at &gt;20%**</th>
<th>ROIC to Exceed AbbVie Cost of Capital Within First Full Year</th>
</tr>
</thead>
</table>

*Represents annual synergies reached after 3 years post-close. Synergy statement has been prepared in accordance with Irish Takeover Rules. **The statement that this transaction is earnings accretive should not be interpreted to mean that the earnings per share in the current or any future financial period will necessarily match or be greater than those for the relevant preceding financial period.
Allergan Business is a Collection of Highly Attractive, Durable Growth Assets

<table>
<thead>
<tr>
<th>Growth Areas</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEDICAL AESTHETICS</td>
<td>$4.3BN</td>
</tr>
<tr>
<td>BOTOX THERAPEUTICS</td>
<td>$2.0BN</td>
</tr>
<tr>
<td>NEUROSCIENCE</td>
<td>$1.2BN</td>
</tr>
<tr>
<td>GASTROINTESTINAL</td>
<td>$1.8BN</td>
</tr>
<tr>
<td>WOMEN’S HEALTH</td>
<td>$0.8BN</td>
</tr>
<tr>
<td>EYE CARE</td>
<td>$2.3BN</td>
</tr>
<tr>
<td>BASE BUSINESS</td>
<td>$15.7BN</td>
</tr>
</tbody>
</table>

Opportunity to Strengthen Allergan’s Franchises and Drive Incremental Growth with AbbVie’s Commercial Capabilities and Strong Global Infrastructure

- Opportunity for significant market expansion; very durable cash pay business
- Botox is leading cosmetic neurotoxin; Allergan has unrivaled product bundle
- Positioned to deliver strong, durable growth through next decade

- Leadership in Migraine, Movement Disorders, Overactive Bladder
- Building a competitive Migraine portfolio anchored on Botox

- Vraylar is fastest growing atypical antipsychotic in the U.S. and represents a clear blockbuster opportunity
- 2 oral CGRPs in late-stage development emerging with competitive profiles
- Opportunity to link Allergan’s Neuroscience portfolio with AbbVie’s R&D capabilities

- Linzess and Viberzi complement AbbVie’s position in Gastrointestinal
- AbbVie will provide critical mass to market-leading IBS franchise

- Market leading oral contraceptive, Lo Loestrin
- Combine with Orilissa to build commercial scale and drive franchise growth

- Strong, durable cash flows
- Opportunity for further growth through new product investments

- Stable and profitable products in both companies’ Base Businesses
- Very efficient P&Ls
- Strong cash flow generation to deploy back into business
Combined Company Comprised of Diverse Portfolio with Leadership Positions in Attractive, High-Growth Markets

<table>
<thead>
<tr>
<th>Immunology</th>
<th>Hematologic Oncology</th>
<th>Medical Aesthetics</th>
<th>Neuroscience</th>
<th>Other Franchises</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Established leadership position with Humira</td>
<td>• Established leadership position with two first-in-class, foundational assets</td>
<td>• Global leadership position in large, growing market</td>
<td>• Multiple growth opportunities</td>
<td>• Women’s Health and Eye Care both large opportunities</td>
</tr>
<tr>
<td>• Launching differentiated, next-gen therapies</td>
<td>• Revenue of &gt;$5BN, with strong DD growth</td>
<td>• Significant opportunity for market expansion</td>
<td>• Franchise revenue of &gt;$3BN</td>
<td>• HCV represents stable source of cash flows</td>
</tr>
<tr>
<td>• Revenue of &gt;$20BN</td>
<td></td>
<td>• Franchise revenue of &gt;$4BN</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Key Brands
- **Humira** (adalimumab)
- **Skyrizi** (risankizumab-rzaa)
- **Linzess**
- **Viberzi** (elenabece)
- **Imbruvica**
- **Botox**
- **Venclexta**
- **Vranylar**
- **Juvéderm Collection**
- **Coolsculpting**
- **Duopax**
- **Lupron Depot**
- **Synagis**
- **Creon**
- **Mavyret**

Pipeline of Attractive Next-Generation Opportunities

Revenue numbers represent 2019 guidance for AbbVie products and 2018 reported product revenue for Allergan.
Combination Creates an Attractive Growth Platform that is Immediately at Scale with Peers

Transaction Significantly Expands and Diversifies AbbVie’s Revenue Base

New AbbVie Growth Platform offers attractive growth potential over the long term

Humira cash flows will be used to pay down incremental debt

*Novartis revenues presented net of the Alcon business unit, which was spun-off in April 2019. 2018 Alcon revenues were $7.1B.

Note: Takeda has a Mar. 31 fiscal year end and acquired Shire in Jan. ‘19. Therefore Shire information is not available for the quarter ended Dec. 31, 2018.

**TAK Revenue is a combination of the 4 traditional quarters of 2018 for Takeda and Shire, with analyst consensus estimate used for Shire for the quarter ended Dec. 31, 2018.

***TAK Op. Cash Flow is a combination of the 4 traditional quarters of 2018 for Takeda and Shire excluding 4Q for Shire because financials nor analyst consensus are available.
AbbVie Comprised of Two High Value Components

Provides immediate scale and profitability to AbbVie’s Growth Platform

**AbbVie Today**

- **Growth Platform**
  - $14BN

- **Humira**
  - $19BN

- **Humira supports infrastructure and R&D investment**
  - Approximately 60% of total company sales
  - Funds R&D engine
  - Supports dividend
  - Supports business development

**New AbbVie**

- **Humira**
  - $19BN

- **Growth Platform**
  - >$29BN

- **Less than 40% of total company sales**
  - Generates robust cash flow up to U.S. LOE in 2023 and beyond
  - Cash flow supports return of capital and serves as resource to pay down debt
  - Standalone scale in 2020
  - Best-in-industry revenue growth prospects
  - Strong operating margin and cash flow
  - Funds R&D engine
  - Supports dividend
  - Supports business development

Revenue numbers based on AbbVie and Allergan respective revenue guidance for 2019 provided on recent earnings calls.
New AbbVie Growth Platform Provides Top-Tier Revenue Growth

2018 – 2023 Revenue CAGR

Growth Platform plus pipeline expected to drive attractive revenue growth through 2023 and beyond

Peer growth calculated from analysts’ consensus estimates as of June 21, 2019. GSK revenue estimates sourced from Bloomberg, all other peer company revenue estimates based on Nasdaq IR. New AbbVie non-Humira revenue growth range based on company estimates.
Potential for Substantial Value Creation

- The transaction offers **significant and immediate accretion*** and an **attractive ROIC**
  - Expect 10% accretion over the first year of combination, with peak accretion of greater than 20%
  - Expect **>$2BN in annual pre-tax synergies and cost savings** in year 3 while protecting funding in key growth franchises
  - ROIC expected to **exceed AbbVie cost of capital within first full year**

- **Supports AbbVie’s top- and bottom-line performance** through Humira U.S. LOE
  - New Growth Platform revenue of more than **$30BN*** in 2020 expected to grow at high-single digits through next decade at attractive operating margin profile

- Generates significant **operating cash flows** ($19BN in combined 2018 cash flow)
  - Committed to **Baa2/BBB credit rating or better** and **debt paydown**; plan to reduce debt by $15-18BN by 2021 with further de-leveraging through 2023
  - Allows for **continued flexibility for business development** to augment innovative pipeline
  - Enables the company to **maintain an attractive dividend growth policy**

- **Integration of the two companies will be highly executable**
  - Major growth franchises untouched by integration activities, allowing them to exclusively focus on maximizing performance
  - Both companies have **considerable experience in the integration of large, complex transactions**

---

**Significant shareholder value to be unlocked via the transaction, offering the opportunity for stock re-rating**

---

*The statement that this transaction is earnings accretive should not be interpreted to mean that the earnings per share in the current or any future financial period will necessarily match or be greater than those for the relevant preceding financial period. **Represents annual synergies reached after 3 years post-close. Synergy statement has been prepared in accordance with Irish Takeover Rules. ***Not intended as revenue guidance; See disclosure statement on Slide 3.
Commercial Presence
Market Leadership in Attractive, Growth Markets

- #1 Position in Immunology
- #2 Position in Hematologic Oncology
- #1 Position in Medical Aesthetics
- Leadership Position in Women’s Health
- #1 Position in Global HCV
- Leadership Position in Eye Care
## Developing Industry-Leading Portfolio of Transformational Therapies to Address Large and Growing $65BN* Market

<table>
<thead>
<tr>
<th>Current–2020</th>
<th>2021–2023</th>
<th>2023+</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Launch Pipeline and Maximize Humira</strong></td>
<td><strong>Indication Expansion</strong></td>
<td><strong>Deliver the Next Transformative Therapy</strong></td>
</tr>
</tbody>
</table>

- **Launch Pipeline and Maximize Humira**
  - Achieve approvals with differentiated labels for SKYRIZI in psoriasis and Upadacitinib (UPA) in RA
  - Secure rapid and broad formulary access
  - Drive meaningful revenue beginning in 2020; expect SKYRIZI and UPA to deliver $>1BN in 2020
  - Maximize Allergan’s gastroenterology franchise

- **Indication Expansion**
  - Accelerate SKYRIZI and UPA growth by gaining approvals and demonstrating best-in-class potential in follow-on indications:
    - SKYRIZI: CD, UC, PsA, AD, HS
    - UPA: PsA, AD, CD, UC, GCA, Axial SpA

- **Deliver the Next Transformative Therapy**
  - Advance early-stage programs exploring innovative molecules and novel targets:
    - ABBV-3373 (Rheum)
    - ABBV-599 (Rheum)
    - ABBV-157 (Derm)
    - ABBV-323 (Gastro)

- **Advance the Next Generation of Innovation**
  - Advance the pre-clinical pipeline to drive the next generation of innovation:
    - >20 ongoing preclinical projects

---

*Based on Evaluate Pharma.
Hematologic Oncology
Established Market Leadership Position in $40BN* Hematologic Malignancies Market

1. Develop Imbruvica and Venclexta as essential treatments in optimizing patient outcomes across multiple hematologic malignancies

2. Transform the therapeutic approach, allowing patients to achieve more durable, deeper responses, including the option for some patients to stop treatment

3. Drive better long-term control of hematological malignancies, ideally with chemotherapy-free regimens

4. Build a broader, deeper pipeline by leveraging our experience in apoptosis and B Cell signaling

Imbruvica
- First-in-class BTK inhibitor
- 4 FDA Breakthrough Therapy designations
- 10 approved indications across 6 distinct patient populations

Venetoclax
- First-in-class Bcl-2 inhibitor
- 5 FDA Breakthrough Therapy designations
- 4 approved indications across CLL and AML populations

*Based on Evaluate Pharma and Kantar Health’s CancerMpact.
Medical Aesthetics
Leadership in an Attractive and Growing $12BN* Market

New product introduction and global expansion will drive significant growth for Medical Aesthetics business

Aesthetics Market Growth Catalysts

- Increasing interest and acceptability of aesthetics
- Global expansion and increasing international penetration
- Largest sales and marketing effort and market leading promotional programs in aesthetics expected to drive continued growth

Launch 1-2 New Products Per Year Over Next Several Years

- **Botox Cosmetic** – expand new indications, formulations, configurations and delivery technologies
- **Juvederm Collection of Fillers** – Expand indications and geographies; Develop next-generation of fillers
- **CoolSculpting** – Launch 3 upgrades in next 3 years, significantly expand customer base

Neuroscience

**Allergan Product Portfolio Provides Immediate Scale to AbbVie**

**Allergan**

- Botox Therapeutic driving durable growth across all indications (chronic migraine, OAB and adult and pediatric spasticity)
- Vraylar continues to be the fastest growing branded antipsychotic
  - Recently approved for bipolar depression
  - Represents a clear blockbuster opportunity in mood disorders; potential expansion into additional indications
- Allergan is building on Botox leadership in migraine market with ubrogepant and atogepant
- Oral CGRPs in late-stage development for acute treatment and prevention of episodic and chronic migraine

**AbbVie**

- Duopa has established AbbVie presence in the advanced Parkinson’s disease market
  - ABBV-951 in Phase 3 development as a less-invasive, non-surgical delivery option; potential to broaden the patient population and strengthen AbbVie’s position in the advanced PD segment
- AbbVie is investing to become a market leader in treating neurodegenerative diseases
  - Advancing technologies & translational capabilities to de-risk and accelerate development
- Evaluating new areas of disease biology to address the growing unmet need in Alzheimer’s and Parkinson’s Disease
  - Focus on misfolded proteins, neuroinflammation and proteostasis
  - ABBV-8E12 (AD); ABBV-0805 (PD)
Other Key Franchises
Market Leadership Positions in HCV, Women’s Health and Eye Care

HCV
- HCV represents large global market, sustainable into the mid-2020s
- Mavyret holds leadership position; emphasis on addressing the remaining unmet medical need
- Mavyret will remain a strong source of cash flow over our long range plan period

Women’s Health
- Elagolix represents significant advance for women suffering from endometriosis and uterine fibroids
- Orilissa expected to be a significant product; revenue of >$2BN by 2025
- Leverage commercial scale to drive strong, profitable growth for market leading oral contraceptive, Lo Loestrin

Eye Care
- Durable $2BN* franchise (ex-Restasis) with multiple late-stage pipeline opportunities
- Expanding presence by targeting unmet needs in retinal disease
- Innovate in glaucoma to drop-less therapy

Stable Base Business
- Sales from legacy products are well positioned for durable performance going forward
- Profitable businesses with minimal opex generate durable cash flows

*Eye Care revenue represents Allergan 2018 Eye Care revenue excluding Restasis revenue of $1.262 billion.
AbbVie Commercial Excellence

30 million +
Patients treated by AbbVie’s medicines every year

175+
Countries where AbbVie’s products help patients

2.3 million
Patients impacted through AbbVie patient support programs globally

- Senior Management experience running diverse healthcare businesses
- Strong track record of commercial execution
- Commercial experience building and maintaining industry-leading franchises
- Exceptional support programs for patients and caregivers
Attractive Pipeline Opportunities
Transaction Allows for Continued Strong Investment in Promising, Innovative Science

Annual R&D Investment*

+80% Growth

$2.8B  $5.1B
2013  2018

Designations Granted

14 Breakthrough Designations
10 Fast Track Designations
 4 Accelerated Approvals
19 Priority Reviews

Major AbbVie Product and Indication Approvals Since 2013

13 FDA Approvals

- Immunology  3 Approvals
- Oncology  6 Approvals
- Neuroscience  1 Approval
- Virology  2 Approvals
- Women's Health  1 Approval

*Adjusted R&D Investment
AbbVie’s Strong Pipeline Augmented with Numerous Attractive Opportunities

<table>
<thead>
<tr>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Registralional/Phase 3</th>
<th>Recent Approvals</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV-011: SCLC</td>
<td>Venclexa: MDS</td>
<td>Venclexa: MM, MCL</td>
<td>Venclexa: 1L CLL, R/R CLL, AML (1L)</td>
</tr>
<tr>
<td>Mivebresib: Solid Tumors</td>
<td>Navitoclax: Myelofibrosis</td>
<td>Imbruvica: FL (1L), FL/MZL (R/R), MCL (1L)</td>
<td>Imbruvica + Rituximab: WM</td>
</tr>
<tr>
<td>ABBV-085: Solid Tumors</td>
<td>Teliso-V: Solid Tumors</td>
<td>Empliciti: MM (1L)</td>
<td>Skyrizi: Psoriasis</td>
</tr>
<tr>
<td>ABBV-155: Solid Tumors</td>
<td>ABT-165: Solid Tumors</td>
<td>Veliparib: NSCLC, BRCA Breast, Ovarian</td>
<td>Orilissa: Endometriosis</td>
</tr>
<tr>
<td>ABBV-151: Solid Tumors</td>
<td>Risankizumab: AD, HS</td>
<td>Rova-T: SCLC (1L)</td>
<td></td>
</tr>
<tr>
<td>ABBV-167: Solid Tumors and Blood Cancers</td>
<td>Upadacitinib: Axial SpA</td>
<td>Risankizumab: CD, UC, PsA</td>
<td></td>
</tr>
<tr>
<td>ABBV-181: Solid Tumors</td>
<td>ABBV-599: RA</td>
<td>Upadacitinib: RA (filed), PsA, CD, UC, AD, GCA</td>
<td></td>
</tr>
<tr>
<td>ABBV-321: Solid Tumors</td>
<td>ABBV-323: UC</td>
<td>Imbruvica: cGvHD (1L)</td>
<td></td>
</tr>
<tr>
<td>ABBV-368: Solid Tumors</td>
<td>ABBV-3373: RA (P1b/2a)</td>
<td>Humira: Pyoderma Gangrenosum (Japan)</td>
<td></td>
</tr>
<tr>
<td>ABBV-621: Solid Tumors</td>
<td>ABBV-812: Alzheimer’s Disease, PSP</td>
<td>ABBV-951: Parkinson’s Disease</td>
<td></td>
</tr>
<tr>
<td>ABBV-744: Solid Tumors and Blood Cancers</td>
<td>Elezanumab: MS</td>
<td>Elagolix: Uterine Fibroids</td>
<td></td>
</tr>
<tr>
<td>ABBV-927: Solid Tumors</td>
<td>ABBV-2222/3067: Cystic Fibrosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABBV-2029: Solid Tumors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABBV-647: Solid Tumors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venclexa: ALL</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AbbVie

As of June 25, 2019. This pipeline represents only medicines; it does not include devices currently in development. Includes programs that may be discontinued and included in synergies if data do not meet acceptable criteria.
Shareholder Value Creation
**Synergies Generate Significant Value**

### Percent of Total Synergies and Cost Reductions

- **SG&A** ~40%
- **R&D** ~50%
- Manufacturing & Supply Chain ~10%

**>$2BN in Year 3**

### Areas of Opportunity

#### SG&A
- Sales and marketing efficiencies
- Reduce duplicate costs across central support functions & IT systems

#### R&D
- Optimize research & early-stage portfolio
- Reduce overlapping resources

#### Manufacturing & Supply Chain
- Leverage procurement spend
- Optimize overhead with combined global footprint

---

**Key franchise funding** levels will remain **untouched** allowing them to **maximize performance**

**Integration** will be **highly executable** as both companies have **considerable experience** with the integration of **large, complex transactions**

---

*Represents annual synergies reached after 3 years post-close. Synergy statement has been prepared in accordance with Irish Takeover Rules.*
## Balance Sheet Strength Will Be Preserved With Robust Cash Flows

### Transaction Financing
- Transaction supported with a $38BN **fully underwritten** bridge facility obtained from Morgan Stanley and MUFG

- The combined company will generate strong durable **operating cash flow** ($19BN in combined 2018 cash flow)
  - Supports AbbVie’s commitment to a strong growing dividend
  - Provides resources for continued expansion of AbbVie’s innovative pipeline through increased R&D funding and mid-to-late stage asset additions

### Robust Cash Flow to Reduce Debt
- AbbVie affirms its commitment to **Baa2/BBB grade credit rating or better**
  - Humira cash flow generation exceeds incremental financing prior to U.S. loss of exclusivity, will be utilized to pay off acquisition financing
  - Committed to **reduce debt by $15BN to $18BN before end of 2021**, with further de-leveraging through 2023
  - Credit metrics targeted to improve to 3.0X net debt to EBITDA in the near term and improve in subsequent years
AbbVie Has a Track Record of Strong Execution, Consistently Meeting or Exceeding Financial Commitments

<table>
<thead>
<tr>
<th>Consistently delivered industry leading financial performance</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Ranked 1st or 2nd in our peer group for both revenue and adjusted EPS growth in every year since becoming an independent company*</td>
</tr>
<tr>
<td>• Met or exceeded both revenue and adjusted EPS guidance in all 25 quarters since becoming an independent company</td>
</tr>
<tr>
<td>• Ranked in top decile of our peer group for operating cash flow growth and adjusted return on equity over past six years</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Delivered Outstanding Shareholder Value and Return of Cash</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Led our peer group in total shareholder return, delivering total returns of 190%** since becoming an independent company</td>
</tr>
<tr>
<td>• Increased quarterly dividend by 168% since becoming an independent company; member of the S&amp;P Dividend Aristocrats Index</td>
</tr>
<tr>
<td>• Returned nearly $44BN to investors via dividends and share repurchases</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Built Market Leadership Positions and Delivered New and Improved Therapies</th>
</tr>
</thead>
<tbody>
<tr>
<td>• We’ve built a strong leadership position in the Immunology market with Humira and continue to innovate with our two next-generation immunology assets</td>
</tr>
<tr>
<td>• Built a tremendous growth platform in Heme-Onc with Imbruvica and Venclexta, assets that are capable of transforming treatment across a wide range of blood cancers</td>
</tr>
<tr>
<td>• Became a global HCV leader with launch of Mavyret, our next-generation HCV cure</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Consistently Increased Investment and Productivity in the R&amp;D Pipeline</th>
</tr>
</thead>
<tbody>
<tr>
<td>• 13 new product or major indication approvals since becoming an independent company</td>
</tr>
<tr>
<td>• $5.1BN in adjusted R&amp;D spend in 2018, growth of over 80% since 2013</td>
</tr>
<tr>
<td>• Built a robust pipeline with 60+ active clinical development programs with more than 30 new products or indications in mid-and late-stage development or under regulatory review</td>
</tr>
</tbody>
</table>

*Measured over the past 1, 2, 3, 4, 5 years or since separation, with, as 2012 pro forma AbbVie EPS is not available, EPS growth referring to the periods from 2013. **Total shareholder return January 1, 2013 through June 19, 2019.
Combination Creates Diversified Biopharmaceutical Company, Well-Positioned for Sustainable Growth

Unique opportunity to acquire **highly attractive** and **durable growth assets** at a highly compelling value

Provides **immediate scale and profitability** to AbbVie’s Growth Platform

Deal significantly mitigates 2023 U.S. Humira LOE

Potential for substantial shareholder value creation

<table>
<thead>
<tr>
<th>Creates Significant Shareholder Value</th>
<th>Generates &gt;$2BN in Synergies and Cost Savings in Year 3*</th>
<th>Significant EPS Accretion: 10% Accretion Over the First Full Year of Combination Peaking at &gt;20%**</th>
<th>ROIC to Exceed AbbVie Cost of Capital Within First Full Year</th>
</tr>
</thead>
</table>

*Represents annual synergies reached after 3 years post-close. Synergy statement has been prepared in accordance with Irish Takeover Rules. **The statement that this transaction is earnings accretive should not be interpreted to mean that the earnings per share in the current or any future financial period will necessarily match or be greater than those for the relevant preceding financial period.